FDA Approves Choline C11 Injection for Prostate Cancer Detection

The U.S. Food and Drug Administration (FDA) announced today the approval for the production and use of Choline C 11 Injection, a PET imaging agent used to help in the detection of prostate cancer.

Choline C 11 Injection is administered intravenously to produce an image that helps to locate specific body sites for follow-up tissue sampling and testing in men with recurrent prostate cancer.

The Mayo Clinic is the first facility approved to manufacture Choline C 11 Injection. The agent is manufactured and distributed by the Mayo Clinic PET Radiochemistry Facility in Rochester, Minn.

To read the full FDA press release, visit: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm319201.htm

This entry was posted in PET Drugs. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s